Eastern Bank Buys 45,508 Shares of Collegium Pharmaceutical, Inc. $COLL

Eastern Bank lifted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 487.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,843 shares of the specialty pharmaceutical company’s stock after purchasing an additional 45,508 shares during the quarter. Eastern Bank owned 0.17% of Collegium Pharmaceutical worth $1,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of COLL. CWM LLC increased its stake in Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,153 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after acquiring an additional 2,169 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Collegium Pharmaceutical by 304.6% in the 2nd quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after acquiring an additional 2,294 shares during the last quarter. Finally, EMC Capital Management bought a new position in Collegium Pharmaceutical in the 2nd quarter valued at approximately $97,000.

Collegium Pharmaceutical Stock Down 1.5%

COLL stock opened at $46.57 on Thursday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 28.93 and a beta of 0.60. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. The business’s 50-day moving average is $46.91 and its two-hundred day moving average is $38.91. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 EPS for the quarter, beating the consensus estimate of $1.89 by $0.36. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The firm had revenue of $209.36 million during the quarter, compared to analyst estimates of $191.25 million. During the same quarter in the prior year, the firm earned $1.61 EPS. The business’s revenue for the quarter was down 18.9% compared to the same quarter last year. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This trade represents a 14.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Colleen Tupper sold 30,000 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $40.53, for a total value of $1,215,900.00. Following the completion of the sale, the chief financial officer owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This trade represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 51,250 shares of company stock worth $2,235,352. Company insiders own 2.51% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on COLL. Truist Financial set a $55.00 target price on Collegium Pharmaceutical in a report on Wednesday, January 7th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $60.00 target price (up previously from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Finally, Needham & Company LLC raised their price target on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $52.80.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.